We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+1.27%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$278M
AUM Growth
-$148M
Cap. Flow
-$149M
Cap. Flow %
-53.67%
Top 10 Hldgs %
51.03%
Holding
53
New
6
Increased
12
Reduced
16
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$8.49M
2
COR icon
Cencora
COR
+$6.02M
3
A icon
Agilent Technologies
A
+$4.89M
4
BIIB icon
Biogen
BIIB
+$4.34M
5
BRKR icon
Bruker
BRKR
+$3.01M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$28.5M
2
CRL icon
Charles River Laboratories
CRL
+$6.77M
3
INSP icon
Inspire Medical Systems
INSP
+$5.91M
4
ABT icon
Abbott
ABT
+$5.68M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.02M

Sector Composition

Rank Sector Weight
1 Healthcare 80.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
A icon
26
Agilent Technologies
A
$41.8B
$4.54M 1.63%
+35,000
New +$4.89M
WST icon
27
West Pharmaceutical
WST
$24.6B
$4.28M 1.54%
13,000
+3,000
+30% +$1.06M
SNN icon
28
Smith & Nephew
SNN
$12.4B
$3.72M 1.34%
150,000
-55,000
-27% -$1.37M
DXCM icon
29
DexCom
DXCM
$33.6B
$3.4M 1.22%
30,000
-5,000
-14% -$632K
BAX icon
30
Baxter International
BAX
$13.8B
$3.35M 1.2%
100,000
-30,000
-23% -$1.11M
TEVA icon
31
Teva Pharmaceuticals
TEVA
$43.1B
$3.25M 1.17%
200,000
+25,000
+14% +$385K
NTRA icon
32
Natera
NTRA
$45.6B
$3.25M 1.17%
30,000
-5,000
-14% -$508K
MRVI icon
33
Maravai LifeSciences
MRVI
$863M
$3.22M 1.16%
450,000
+85,000
+23% +$734K
MEDP icon
34
Medpace
MEDP
$16.7B
$3.09M 1.11%
7,500
– –
HUM icon
35
Humana
HUM
$45.6B
$2.8M 1.01%
7,500
-12,500
-63% -$4.22M
BRKR icon
36
Bruker
BRKR
$8.72B
$2.55M 0.92%
+40,000
New +$3.01M
RGEN icon
37
Repligen
RGEN
$9.2B
$1.89M 0.68%
+15,000
New +$2.35M
ABT icon
38
Abbott
ABT
$190B
– –
-50,000
Closed -$5.68M
BMRN icon
39
BioMarin Pharmaceuticals
BMRN
$13.6B
– –
-57,500
Closed -$5.02M
BNTX icon
40
BioNTech
BNTX
$23.3B
– –
-25,000
Closed -$2.31M
CI icon
41
Cigna
CI
$72.3B
– –
-10,000
Closed -$3.63M
CRL icon
42
Charles River Laboratories
CRL
$13.6B
– –
-25,000
Closed -$6.77M
GEHC icon
43
GE HealthCare
GEHC
$32.4B
– –
-40,000
Closed -$3.64M
GPCR icon
44
Structure Therapeutics
GPCR
$3.73B
– –
-4,464
Closed -$191K
INSP icon
45
Inspire Medical Systems
INSP
$1.67B
– –
-27,500
Closed -$5.91M
OPCH icon
46
Option Care Health
OPCH
$3.54B
– –
-110,000
Closed -$3.69M
RVTY icon
47
Revvity
RVTY
$12.8B
– –
-30,000
Closed -$3.15M
STVN icon
48
Stevanato
STVN
$5.71B
– –
-83,039
Closed -$2.67M
UNH icon
49
UnitedHealth
UNH
$363B
– –
-10,000
Closed -$4.95M
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$10.5B
– –
-300,000
Closed -$28.5M
1
2
3

Similar funds

AFP
ATX Financial Planning Austin, Texas $132M AUM
TCPW
Twin City Private Wealth Winston-Salem, North Carolina $132M AUM 11.31% 1-Year Est. Return
PCGDR
Pangea Capital Gestao de Recursos Rio De Janeiro $131M AUM
ACM
Alcosta Capital Management San Ramon, California $131M AUM 34.7% 1-Year Est. Return
9C
9823 Capital Dallas, Texas $132M AUM
STFP
Signal Tree Financial Partners Copley, Ohio $132M AUM 15.43% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $131M AUM 7.53% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return

Sivik Global Healthcare's Q2 2024 Portfolio in Review

As of Q2 2024, Sivik Global Healthcare held 53 positions worth $278M, down 35% from $427M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sivik Global Healthcare withdrew a net $149M in Q2 2024, closing 15 positions and reducing 16 holdings. Its most notable exit was State Street SPDR S&P Biotech ETF, an estimated $28.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 58% a quarter earlier.

Against the trend, Sivik Global Healthcare opened a new position in Merck worth $8.15M.

  • Sivik Global Healthcare's largest Q2 2024 buy was Merck: 65,874 shares worth $8.15M.
  • Sivik Global Healthcare added most to Biogen in Q2 2024, an estimated $4.34M increase.
  • Sivik Global Healthcare's biggest Q2 2024 reduction was Humana, cutting an estimated $4.22M.
  • Sivik Global Healthcare fully exited State Street SPDR S&P Biotech ETF in Q2 2024, selling an estimated $28.5M.
  • Sivik Global Healthcare's ten largest holdings make up 51% of its $278M portfolio in Q2 2024.
  • Sivik Global Healthcare opened 6 new positions and closed 15 in Q2 2024.
  • Sivik Global Healthcare's portfolio value fell 35% quarter-over-quarter to $278M.

Based on Sivik Global Healthcare's 13F filing for Q2 2024, filed 29 Jul 2024.